Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin reported encouraging long-term results from the Phase 1/2 KOMET-007 trial evaluating ziftomenib plus 7+3 chemotherapy in newly diagnosed AML. In the NPM1-mutant cohort, the regimen achieved a 96% composite complete remission rate and a 94% 12-month overall survival rate, significantly outperforming historical benchmarks for standard-of-care chemotherapy alone. The KMT2A-rearranged cohort also showed strong activity with a 90% composite complete remission rate and 71% 12-month overall survival, with high rates of measurable residual disease negativity in both subtypes.
Key figures
- Drug Name
- ziftomenib (KOMZIFTI)
- Phase Of Trial
- Phase 1/2
- Npm1 m crc
- 96%
- Npm1 m orr
- 98%
- Kmt2a r crc
- 90%
- Kmt2a r orr
- 92%
- Npm1 m 12mo os
- 94%
- Kmt2a r 12mo os
- 71%
- Npm1 m mrd neg local
- 85%
- Kmt2a r mrd neg local
- 82%
- Npm1 m 60day mortality
- 2%
- Npm1 m median followup
- 17.6 months
- Npm1 m mrd neg central
- 56%
- Kmt2a r median followup
- 11.0 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.